[A dose-response meta-analysis on the relationship between daily tea intake and cardiovascular mortality based on the

K F Liu1, Y Xue1, C Y Lu1

  • 1Department of Pharmacy, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Insights

Drinking tea daily is linked to lower cardiovascular disease (CVD) mortality. This meta-analysis suggests that regular tea consumption, particularly green tea, offers protective benefits against CVD deaths.

Area of Science:

  • Cardiovascular Health
  • Nutritional Epidemiology
  • Preventive Medicine

Background:

  • Cardiovascular diseases (CVD) remain a leading cause of mortality worldwide.
  • Lifestyle factors, including dietary habits, play a crucial role in CVD prevention.
  • The potential health benefits of tea consumption have been investigated, but conclusive evidence on its impact on CVD mortality is needed.

Purpose of the Study:

  • To conduct a comprehensive meta-analysis exploring the association between daily tea intake and cardiovascular disease (CVD) mortality.
  • To evaluate the dose-response relationship between tea consumption and CVD mortality.
  • To identify potential differences in this association across various populations and tea types.

Main Methods:

  • A systematic search of multiple databases (PubMed, EMbase, Cochrane, etc.) was performed up to June 2020.
  • Included 21 cohort or case-control studies with over 1.3 million participants and reported 38,222 CVD deaths.
  • Utilized dose-response meta-analysis, sensitivity analysis, publication bias assessment, and GRADE methodology for quality evaluation.

Main Results:

  • Increased daily tea intake showed a non-linear inverse relationship with CVD mortality, with each additional cup reducing mortality by approximately 3%.
  • Drinking 1-8 cups of tea daily was associated with an 8-16% reduction in CVD mortality compared to non-drinkers.
  • Subgroup analyses indicated significant reductions in CVD mortality for men, women, Asians, and green tea drinkers, with non-smokers showing the most pronounced benefit.

Conclusions:

  • Daily tea consumption is significantly associated with reduced cardiovascular disease mortality.
  • An appropriate daily intake of tea, particularly green tea, is recommended for cardiovascular health benefits.
  • While evidence suggests benefits, the GRADE assessment indicated low-grade evidence, warranting further high-quality research.

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
4.3K
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
563
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
184
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
45
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.8K
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
329